Terfenadine

Terfenadine
Systematic (IUPAC) name
4-[4-(hydroxy-diphenyl-methyl)-1-piperidyl]- 1-(4-tert-butylphenyl)-butan-1-ol
Identifiers
CAS number	50679-08-8
ATC code	R06AX12
PubChem	5405
DrugBank	APRD00606
Chemical data
Formula	C32H41NO2
Mol. mass	471.673 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	70%
Metabolism	?
Half life	3.5 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

WikiDoc Resources for Terfenadine
Articles
Most recent articles on Terfenadine Most cited articles on Terfenadine Review articles on Terfenadine Articles on Terfenadine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Terfenadine Images of Terfenadine Photos of Terfenadine Podcasts & MP3s on Terfenadine Videos on Terfenadine
Evidence Based Medicine
Cochrane Collaboration on Terfenadine Bandolier on Terfenadine TRIP on Terfenadine
Clinical Trials
Ongoing Trials on Terfenadine at Clinical Trials.gov Trial results on Terfenadine Clinical Trials on Terfenadine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Terfenadine NICE Guidance on Terfenadine NHS PRODIGY Guidance FDA on Terfenadine CDC on Terfenadine
Books
Books on Terfenadine
News
Terfenadine in the news Be alerted to news on Terfenadine News trends on Terfenadine
Commentary
Blogs on Terfenadine
Definitions
Definitions of Terfenadine
Patient Resources / Community
Patient resources on Terfenadine Discussion groups on Terfenadine Patient Handouts on Terfenadine Directions to Hospitals Treating Terfenadine Risk calculators and risk factors for Terfenadine
Healthcare Provider Resources
Symptoms of Terfenadine Causes & Risk Factors for Terfenadine Diagnostic studies for Terfenadine Treatment of Terfenadine
Continuing Medical Education (CME)
CME Programs on Terfenadine
International
Terfenadine en Espanol Terfenadine en Francais
Business
Terfenadine in the Marketplace Patents on Terfenadine
Experimental / Informatics
List of terms related to Terfenadine

Overview

Terfenadine is an antihistamine formerly used for the treatment of allergic conditions. It was marketed under various brand names including Seldane in the United States, Triludan in the United Kingdom, and Teldane in Australia. It was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

Terfenadine is a prodrug, generally completely metabolised to the active form fexofenadine by intestinal CYP3A4. Terfenadine itself, however, has a cardiotoxic effect and may be absorbed and reach myocytes if the patient is concurrently taking a CYP3A4 inhibitor (e.g. erythromycin, grapefruit juice).